Allkosは,裁判の失敗によりAK006の薬物開発を停止し,雇用を削減し,株式価値を失う. Allakos halts AK006 drug development due to failed trial, cutting jobs and losing stock value.

慢性自発性疹の治療のためのAK006の第1相臨床試験は,期待された効果を示さなかったとAllakos Inc.は発表した. Allakos Inc. announced that its phase 1 clinical trial of AK006 for treating chronic spontaneous urticaria did not show expected benefits. 同社はAK006開発を停止し,労働力の75%を削減し,約15人の従業員を保留する. The company will halt AK006 development, cutting its workforce by 75% and retaining about 15 employees. 改造には3千4百万から3千8百万ドルの費用がかかる予定だ. The restructuring is expected to cost $34 million to $38 million. Allkosの株式は,この発表の後,74.8%減少した. Allakos' stock dropped 74.8% following the announcement.